Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ovarian Neoplasms

Free Subscription 12.08.2024 1 Am J Obstet Gynecol 1 BMC Cancer 8 Gynecol Oncol 1 J Natl Cancer Inst 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Obstet Gynecol

1. JOCHUM F, Dumas E, Gougis P, Hamy AS, et al
   Survival Outcomes of Primary versus Interval Cytoreductive Surgery for FIGO IV Ovarian Cancer (SOFI-4): a Nationwide Population-based Target Trial Emulation.
   Am J Obstet Gynecol. 2024 Aug 5:S0002-9378(24)00818.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. LIU D, Li R, Wang Y, Li D, et al
   Identification and validation of genes associated with prognosis of cisplatin-resistant ovarian cancer.
   BMC Cancer. 2024;24:508.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

3. VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al
   Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
   Gynecol Oncol. 2024;189:111-118.
   PubMed         Abstract available
   
   
4. AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al
   Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
   Gynecol Oncol. 2024;187:241-248.
   PubMed         Abstract available
   
   
5. YUAN G, Zhang K, Zheng H, Wu Y, et al
   Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
   Gynecol Oncol. 2024;187:212-220.
   PubMed         Abstract available
   
   
6. STROOT IAS, Bart J, Hollema H, Jalving M, et al
   Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
   Gynecol Oncol. 2024;187:198-203.
   PubMed         Abstract available
   
   
7. MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al
   Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
   Gynecol Oncol. 2024;187:170-177.
   PubMed         Abstract available
   
   
8. VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al
   Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
   Gynecol Oncol. 2024;187:113-119.
   PubMed         Abstract available
   
   
9. PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al
   Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
   Gynecol Oncol. 2024;187:92-97.
   PubMed         Abstract available
   
   
10. LIANG S, Ge H, Zhou S, Tang J, et al
    Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST.
    Gynecol Oncol. 2024;187:64-73.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

11. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed         Abstract available
    
    

    
    PLoS One

12. TANG F, Hummitzsch K, Rodgers RJ
    Unique features of KGN granulosa-like tumour cells in the regulation of steroidogenic and antioxidant genes.
    PLoS One. 2024;19:e0308168.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.